Crackling Noise

Crackling noise arises when a system responds to changing external conditions through discrete, impulsive events spanning a broad range of sizes. A wide variety of physical systems exhibiting crackling noise have been studied, from earthquakes on faults to paper crumpling. Because these systems exhibit regular behavior over many decades of sizes, their behavior is likely independent of microscopic and macroscopic details, and progress can be made by the use of very simple models. The fact that simple models and real systems can share the same behavior on a wide range of scales is called universality. We illustrate these ideas using results for our model of crackling noise in magnets, explaining the use of the renormalization group and scaling collapses. This field is still developing: we describe a number of continuing challenges

Neuroinflammatory signals enhance the immunomodulatory and neuroprotective properties of multipotent adult progenitor cells

Introduction: Stem cell-based therapies are currently widely explored as a tool to treat neuroimmune diseases. MAPC (Multipotent Adult Progenitor Cells) have been suggested to have strong immunomodulatory and neuroprotective properties in several experimental models. In this study, we investigate whether MAPC are of therapeutic interest for neuroinflammatory disorders such as multiple sclerosis (MS), by evaluating their capacities to modulate crucial pathological features and gain insights in the molecular pathways involved. Methods: Rat MAPC (rMAPC) were treated with combinations of pro-inflammatory cytokines that are closely associated with neuroinflammatory conditions, a process called licensing. mRNA expression of immunomodulatory molecules, chemokines and chemokine receptors was investigated. The migratory potential of licensed rMAPC towards a broad spectrum of chemokines was tested in a Transwell assay. Furthermore, the effect of licensing on the ability of rMAPC to attract and suppress the proliferation of encephalitogenic T cells was assessed. Finally, neuroprotective properties of rMAPC were determined in the context of protection from oxidative stress of oligodendrocytes. Therefore, rMAPC were incubated with conditioned medium of OLN93 cells subjected to sub-lethal doses of hydrogen peroxide (H2O2) and the gene expression of neurotrophic factors was assessed. Results: After licensing, a wide variety of immunomodulatory molecules and chemokines, including Nitric Oxide synthase (iNOS) and fractalkine, was up-regulated by rMAPC. The migratory properties of rMAPC towards various chemokines were also altered. In addition, rMAPC were found to inhibit antigen specific T cell proliferation and this suppressive effect was further enhanced after pro-inflammatory treatment. This phenomenon was partially mediated through iNOS or cyclooxygenase-2 (COX-2). Activated rMAPC secreted factors that led to attraction of myelin specific T cells. Finally, exposure of rMAPC to in vitro simulated neurodegenerative environment induced the up-regulation of mRNA levels of vascular endothelial growth factor (VEGF) and ciliary neurotrophic factor (CNTF). Factors secreted by rMAPC in response to this environment partially protected OLN93 cells from H2O2 induced cell death. Conclusions: rMAPC possess immune modulatory and neuroprotective properties which are enhanced in response to neuroinflammatory signals. These findings thereby warrant further research to evaluate MAPC transplantation as a therapeutic approach in diseases with an immunological and neurodegenerative component such as MS.The authors would like to thank Ms. Katrien Wauterickx, Ms. Christel Bocken and Mr. Jo Janssen (Hasselt University, Biomedical Research institute) for overall technical assistance. Additionally, we gratefully thank Ms. Ellen Van Houtven (ReGenesys) for her assistance in designing the migration assays. This research was supported by the Belgian Charcot Foundation

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

Background Inflammatory bowel diseases (IBD) are chronic relapsing diseases in which pro-inflammatory immune cells and cytokines induce intestinal tissue damage and disability. Mesenchymal stromal cells (MSCs) exert powerful immunomodulatory effects and stimulate tissue repair. Aim To review the current data on mesenchymal stromal cell therapy in IBD. Method We searched PubMed and ‘ClinicalTrials.gov’ databases using the terms ‘mesenchymal stromal cells’, ‘mesenchymal stem cell transplantation’, ‘inflammatory bowel diseases’, ‘Crohn disease’ and ‘colitis, ulcerative’. Additional publications were identified from individual article reference lists. Results MSCs include inhibition of Th1/Th17 lymphocytes and recruitment of regulatory T lymphocytes, induction of antigen-presenting cells into a regulatorylike profile, and stimulation of epithelial cell differentiation and proliferation. More than 200 patients with refractory fistulas have been treated with local injections of MSCs, resulting in complete response in more than half, and in overall response in approximately two thirds of patients. In refractory luminal Crohn’s disease, 49 cases of systemic MSC infusions have been reported, while trials with autologous MSCs resulted in mitigated responses, studies using allogeneic MSCs were promising, with around 60% of patients experiencing a response and around 40% achieving clinical remission. Conclusions Mesenchymal stromal cells might represent a promising therapy for IBD, especially for Crohn’s disease. There remain many unsolved questions concerning the optimal origin and source of mesenchymal stromal cells, dosage and modalities of administration. Moreover, mesenchymal stromal cells still need to prove their effectiveness compared with conventional treatments in randomised controlled trials